The purpose of this study was to determine the outcome of high-dose therapy with autologous hematopoietic stem cell support (autotransplants) in men with breast cancer. We studied 13 men receiving autotransplants for breast cancer and reported to the Autologous Blood and Marrow Transplant Registry (ABMTR) by 10 centers. Six men had stage 2 breast cancer, four had stage 3, and three had metastatic breast cancer. Of twelve tumors tested, all were estrogen receptor positive. Median age at transplant was 50 years. The most common conditioning regimen was cyclophosphamide, thiotepa and carboplatin (n = 5); the remaining eight men received other alkylator-based regimens. Three men received bone marrow, eight received blood stem cells, and two received both for hematopoietic support. All patients had hematopoietic recovery. There were no unexpected regimen-related toxicities. Of 10 men receiving autotransplants as adjuvant therapy, three relapsed 3, 5 and 50 months post-transplant and died 16, 19 and 67 months post-transplant. Seven of 10 are disease-free with median follow-up of 23 months (range 6-50 months). Of three men treated for metastatic breast cancer, one had progressive disease and two recurrent disease at 6, 7 and 16 months post-transplant. In conclusion, results of autotransplants for male breast cancer appear similar to those reported for women receiving autotransplants for breast cancer. Keywords: male breast cancer; autotransplant Male breast cancer accounts for fewer than 1% of all breast cancers. The annual incidence is Ͻ1 per 100 000 males.
women, possibly as a result of delays in diagnosis. Anatomic factors may also contribute. 3 The median age of men with breast cancer is 5 to 10 years older than women with breast cancer. [1] [2] [3] [4] [5] [6] [7] While 64% of premenopausal and 75% of post-menopausal women have estrogen receptor (ER) positive cancers and 58% and 53%, respectively, have progesterone receptor (PR) positive tumors, according to a large study by Clark and colleagues, 8 80-90% of men have ER and PR positive breast cancer. [1] [2] [3] [4] [5] [6] [7] Recent advances in the molecular biology of breast cancer have allowed detection of differences in the BRCA1 and BRCA2 mutations in hereditary and spontaneously occurring female and male breast cancers (reviewed in Refs 9 and 10).
The standard therapy of breast cancer in men is similar to treatment in women, including surgery, radiation, hormone therapy and chemotherapy. [1] [2] [3] [4] [5] [6] [7] Some investigators report outcomes in men to be the same as in women, when patients are matched for histopathology, receptor state and disease stage. [3] [4] [5] [6] Others suggest that men have poorer outcomes than women despite lower histologic grade, high ER content and small size. 6 Increasing numbers of women now receive high-dose chemotherapy with autologous hematopoietic stem cell support (autotransplant) for both metastatic and high-risk stage 2/3 breast cancer. 11 We studied 13 men receiving high-dose chemotherapy with an autotransplant and reported to the Autologous Blood and Marrow Transplant Registry (ABMTR).
Methods
Thirteen men were identified among 3254 autotransplants for breast cancer reported to the ABMTR between January 1989 and January 1996 by 107 centers. Detailed patient-, disease-, treatment-and outcome-related data were obtained on standard ABMTR report forms.
The ABMTR is a voluntary working group of more than 120 transplant centers primarily in North and South America that contribute detailed data on their autologous blood and bone marrow transplants to the Statistical Center at the Medical College of Wisconsin. Participants are required to report all consecutive autotransplants; compliance is monitored by on-site audits. The ABMTR database includes data on about 50% of the autotransplants done in North and South America since 1989. Patients are followed longitudinally. Computerized error checks, physician review of submitted data, and on-site audits of participating centers ensure data quality.
Results
Thirteen subjects were treated at 11 centers. Table 1 lists features at diagnosis. Median age was 49 years (range 32-60 years). Of 12 cancers tested, 12 were ER positive and 10 were PR positive. Twelve men had a mastectomy. One received pre-surgery chemotherapy. Ten men received autotransplants as adjuvant treatment, six for stage 2 disease (all with greater than 10 positive ipsilateral axillary lymph nodes) and four for stage 3 disease (one with inflammatory breast cancer). All had received prior standard-dose adjuvant chemotherapy with an anthracyclinecontaining regimen. Three men had autotransplants for metastatic disease. One presented with stage 4 disease; two developed metastases after presenting with stage 1 and stage 2 disease. All three men with metastatic disease had received chemotherapy treatment for their metastases with an anthracycline-containing regimen. One had a complete response, one a partial response and one stable disease prior to autotransplant.
Twelve of 13 men had Karnofsky performance scores of 90% or 100% at the time of autotransplant. One patient with metastatic disease had a Karnofsky score of 80%. The one patient receiving two autotransplants had a Karnofsky score of 70% prior to the second transplant. Median interval Inf = inflammatory; ER = estrogen receptor; PR = progesterone receptor; NT = not tested; LNs = lymph nodes; Adj = adjuvant; Met = metastatic; C = chemotherapy; G = granulocyte colony-stimulating factor; GM = granulocyte-macrophage colony-stimulating factor; B = blood; BM = bone marrow; Cy = cyclophosphamide; T = thiotepa; Cb = carboplatin; Ta = taxol; B = carmustine; P = cisplatinum; A = adriamycin; E = etoposide; I = ifosfamide; Mel = melphalan; HGF = hematopoietic growth factor; Epo = erythropoietin. from diagnosis to autotransplant was 6 months (range, 4-9 months) for men with stage 2 or 3 disease and 12, 31 and 32 months for the three with metastatic disease. Table 1 also lists types of graft, mobilizing agents, and high-dose therapy regimens. One patient (No. 13) received a planned second autotransplant. Mobilized peripheral blood (n = 9), bone marrow (n = 3) or both (n = 2) were used for hematopoietic stem cell support. Five peripheral blood collections were mobilized with hematopoietic growth factors alone and six with growth factors and chemotherapy. High-dose therapy regimens consisted primarily of alkylating drugs. The most common regimen was cyclophosphamide, thiotepa and carboplatin (n = 5). Eleven of 13 men received hematopoietic growth factors after graft infusion. Nine of the 10 men with stage 2 or 3 disease received primary chest wall radiation, two before, and seven after autotransplant. Six of 10 received hormonal therapy (tamoxifen) after autotransplant. One of the men with metastatic disease received local radiation therapy to the chest wall after autotransplant.
Median day to absolute neutrophil count Ͼ1.0 × 10 9 /l was 12 days (range 8-22 days). Median day to platelet count Ͼ25 × 10 9 /l was 14 days (range 6-20 days). In three autotransplants, the exact day of achieving absolute neutrophil count Ͼ1.0 × 10 9 /l was not reported and in four, the day to platelet count Ͼ25 × 10 9 /l was not available. However, all patients had evidence of hematopoietic recovery and became transfusion-independent. No patient developed myelodysplasia or other bone marrow disorder. No grade 4 (World Health Organization) non-hematologic toxicities were reported. Table 2 lists patient outcome. Seven of 10 men receiving autotransplants as adjuvant therapy are disease-free with a median follow-up of 23 months (range 6-50 months). Three men relapsed at 3, 5 and 50 months post-transplant and subsequently died 16, 19 and 67 months post-transplant.
All three men treated for metastatic breast cancer had evidence of progressive or recurrent disease after autotransplant. The patient who achieved a complete response to standard-dose chemotherapy received two autotransplants and relapsed 5 months after his second autotransplant. The patient transplanted after a partial response to standard-dose chemotherapy failed to achieve a complete response and progressed 7 months post-transplant. The patient transplanted with stable disease achieved a complete response after autotransplant but relapsed 16 months later. Two subsequently died 12 and 23 months post-transplant. One is alive with progressive breast cancer 27 months posttransplant.
Discussion
This ABMTR report is the only study of men receiving autotransplants for breast cancer. The treatment was well tolerated with no regimen-related deaths and no unexpected non-hematologic toxicities. The toxicity appears equivalent to previously published reports in women receiving autotransplants for breast cancer. [11] [12] [13] [14] Although the number of subjects is small, the efficacy of autotransplant in these 13 men with high-risk breast cancer appears similar to results reported in women. 11, 12 Outcomes of the patients with metastatic disease were disappointing, however only three patients were available for analysis. Seven of 10 men receiving autotransplants as adjuvant therapy are alive and disease-free. These results are encouraging when compared to historic results of treatment with standard chemo-, radiation and hormonal therapy for patients with locally advanced disease. [1] [2] [3] [4] [5] [6] [7] However, evaluation of more cases and longer follow-up will be necessary to determine the incidence of late recurrence and possibility for cure in this population. The relative efficacy of standard and high-dose chemotherapy in men with breast cancer is probably not evaluable given the rarity of this disease. However, these data suggest that indications for high-dose therapy developed in the ongoing randomized studies in women will be applicable to men. Additionally, it seems reasonable to recommend inclusion of men in randomized studies that examine the role of autotransplant for breast cancer.
